Takeda, the Japanese pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has approved the use of ixazomib as a treatment for relapsed myeloma patients who have received at least one prior line of treatment. Ixazomib is the first, and currently only oral proteasome inhibitor, to be licensed and is indicated for use in combination with Revlimid® and dexamethasone. The approval is based on results of the Phase III TOURMALINE-MM1 trial which showed that patients treated with ixazomib, Revlimid and dexamethasone significantly extended progression-free survival compared to patients treated with Revlimid and dexamethasone alone. The drug is being marketed under the brand name, Ninlaro®.


Read full article